Marc Martinez- Llordella
Company: Quell Therapeutics
Job title: VP, Biology
Dr Marc Martinez-Llordella is co-founder and Vice President Biology at Quell Therapeutics. Marc has forged a deep academic research career focused on Tregs biology and immunological tolerance. His most recent research as Senior Lecturer at King’s College London has combined pre-clinical models and immunomonitoring analysis of clinical trials to identify new strategies to modulate Treg homeostasis and function. Marc’s group has investigated the role of microenviromental cues such as IL-2 availability and inflammation shaping the phenotypic characteristics of tissue resident T cells. His translational research has supported the implementation of new tolerogenic therapies such as low-dose IL-2 and CAR-Tregs into transplantation and autoimmunity. Prior to that he worked in Professor Jeff Bluestone’s lab at University College San Francisco where he carried out post-doctoral research on the transcriptional profile of CD28 signalling in T cell activation and the analysis of Treg phenotypic plasticity in autoimmunity. Marc holds a PhD from the University of Barcelona focussed on the identification of transcriptional and phenotypic biomarkers to predict transplantation tolerance.
Treg-based Therapies to Induce Immune Tolerance in Transplantation & Autoimmunity 12:00 pm
Lessons learned from Treg-directed therapies in liver transplantation (polyclonal Tregs vs low dose IL-2 therapy) Engineered Tregs for the modulation of antigen-specific responses Quell Therapeutics strategy to enhance Treg therapiesRead more
day: Day One